| Literature DB >> 25428829 |
Anne Quinquenel1, Christophe Willekens, Jehan Dupuis, Bruno Royer, Loic Ysebaert, S De Guibert, Anne-Sophie Michallet, Pierre Feugier, Romain Guieze, Vincent Levy, Alain Delmer.
Abstract
We report our experience on bendamustine and rituximab (BR) combination in 26 patients with chronic lymphocytic leukemia (CLL) complicated by autoimmune hemolytic anemia (AIHA). At the time of BR initiation, 88% of the patients had already been treated for AIHA and CLL was progressive regardless of AIHA in all patients but one. Overall response rates were 81% for AIHA and 77% for CLL. Median time to next treatment was 28.3 months and 26.2 months for AIHA and CLL, respectively. BR therapy may represent a good and safe therapeutic option in this setting where adequate control of CLL seems important for long-term AIHA response.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25428829 DOI： 10.1002/ajh.23909
Source DB: PubMed Journal: Am J Hematol ISSN： 0361-8609 Impact factor: 10.047